Manifold Bio
Manifold Bio develops AI-guided, in-vivo protein discovery technologies for tissue-targeted biologics and pharmaceutical research partnerships.
Founded
2019Manifold Bio develops AI-guided, in-vivo protein discovery technologies for tissue-targeted biologics and pharmaceutical research partnerships.
Manifold's mCodes attach inert peptide barcodes to candidate proteins so tissue distribution can be measured with detectors and sequencing. The company says this enables multiplexed comparisons across many molecules and tissues in living systems, linking protein design to observed biological behavior.
The mBER-2 report describes designing more than 50 million binders and testing millions in animals, including over one million in nonhuman primates. Those measurements support models of targeting and distribution, while the company continues to characterize the resulting candidates rather than presenting them as approved medicines.
Source: manifold.bio
Manifold frames its opportunity around tissue-targeted medicines across modalities, combining internal development with strategic partnerships. Its official pipeline describes CNS targets such as amyloid beta and tau alongside peripheral delivery research, including an undisclosed adipose-tissue target.
The company presents brain delivery as an initial area and plans to expand toward other tissues and cell types. These are discovery-stage research directions and partner programs; the public materials do not identify a marketed drug or establish clinical efficacy.
Source: manifold.bio
Manifold Bio combines AI-guided protein design with multiplexed molecular measurement in living systems. Its mDesign engine includes mCodes for tracking protein distribution and mBER for generating antibody binders, while the mShuttle portfolio explores tissue-targeted delivery across modalities.
The company describes an internal pipeline of biologic candidates across CNS and peripheral targets, alongside work with pharmaceutical partners. These programs remain in discovery and development; the platform's engineered binders and shuttles are investigational constructs rather than marketed drugs.
Source: manifold.bio